GlassScriptPhysician profile
Melanie Williams
NPI 1316406168
$5,271.28
in general payments reported to CMS, 2019-2025
25 companies · $3,227 in 2025
The $3,227 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $210 · 2024: $1,834 · 2025: $3,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,010 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,010.44 |
| Education | $260.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.42 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $578.98 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $429.44 | 2024-2025 | |
| Janssen Biotech, INC. | $379.89 | 2023-2025 | Tremfya |
| Ucb, INC. | $355.89 | 2025 | Bimzelx |
| Lilly USA, LLC | $313.09 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $312.49 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $293.10 | 2023-2025 | |
| Pfizer INC. | $279.71 | 2024-2025 | |
| Incyte Corporation | $263.30 | 2024-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $221.55 | 2023-2025 | |
| Dermavant Sciences, INC. | $189.34 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $184.98 | 2024-2025 | Sotyktu |
| Hill Dermaceuticals, INC. | $153.65 | 2025 | Tolak |
| Arcutis Biotherapeutics, INC. | $152.58 | 2024-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $103.18 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $92.46 | 2023-2025 | Otezla |
| Organon LLC | $91.12 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.61 | 2024-2025 | Spevigo |
| Galderma Laboratories, L.P. | $45.40 | 2024-2025 | Nemluvio, Dysport |
| Almirall LLC | $28.37 | 2025 | Klisyri |
| Leo Pharma INC. | $27.49 | 2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.85 | 2024 | Jublia, Arazlo, Cabtreo |
| Journey Medical Corporation | $19.19 | 2025 | |
| Verrica Pharmaceuticals INC. | $17.20 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.